Last reviewed · How we verify
AlphaMedix
AlphaMedix is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell proliferation.
AlphaMedix is a small molecule that targets the PI3K/AKT pathway to inhibit cancer cell proliferation. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | AlphaMedix |
|---|---|
| Also known as | Pb212-octreotide analog |
| Sponsor | Orano Med LLC |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AlphaMedix works by selectively inhibiting the PI3K/AKT pathway, which is involved in cell survival and proliferation. This inhibition leads to a decrease in cancer cell growth and an increase in apoptosis. By targeting this pathway, AlphaMedix has shown promise in treating various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (PHASE1)
- Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |